The first decade of angiogenesis research led to the isolation and clo
ning of angiogenesis stimulatory molecules. More recent studies have l
ed to the isolation and cloning of angiogenesis inhibitors. These mole
cules include both peptides and small molecular weight compounds. The
mechanisms of action of these compounds are not fully understood, but
will likely involve modulation of the phosphoinositol-3-kinase and MAP
kinase pathways. These agents have impressive antitumor activity in e
xperimental animals, and may prove to be extremely useful for the trea
tment of malignant and nonmalignant disorders in patients.